MA49013A - Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 - Google Patents
Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2Info
- Publication number
- MA49013A MA49013A MA049013A MA49013A MA49013A MA 49013 A MA49013 A MA 49013A MA 049013 A MA049013 A MA 049013A MA 49013 A MA49013 A MA 49013A MA 49013 A MA49013 A MA 49013A
- Authority
- MA
- Morocco
- Prior art keywords
- derivatives useful
- heterocyclic derivatives
- new heterocyclic
- shp2 inhibitors
- shp2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2017051690 | 2017-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49013A true MA49013A (fr) | 2021-05-05 |
Family
ID=63584301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049013A MA49013A (fr) | 2017-03-23 | 2018-03-23 | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10988466B2 (fr) |
| EP (1) | EP3601239A4 (fr) |
| JP (3) | JP6878615B2 (fr) |
| KR (4) | KR20240026521A (fr) |
| AU (3) | AU2018239542C1 (fr) |
| CA (1) | CA3057582C (fr) |
| CL (2) | CL2019002698A1 (fr) |
| CO (1) | CO2019011678A2 (fr) |
| EA (2) | EA201992253A1 (fr) |
| MA (1) | MA49013A (fr) |
| MX (4) | MX2019011330A (fr) |
| NZ (1) | NZ758458A (fr) |
| PH (1) | PH12019502175A1 (fr) |
| SG (1) | SG11201908820VA (fr) |
| TW (1) | TWI664175B (fr) |
| WO (1) | WO2018172984A1 (fr) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10280171B2 (en) | 2016-05-31 | 2019-05-07 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| EP4108659A1 (fr) * | 2016-06-07 | 2022-12-28 | Jacobio Pharmaceuticals Co., Ltd. | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs shp2 |
| EA036446B1 (ru) | 2016-06-14 | 2020-11-11 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
| CN116478132A (zh) | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
| EP3515916B1 (fr) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation |
| TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
| AU2018239542C1 (en) | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
| US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| CA3074690A1 (fr) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Compositions d'inhibiteur de la shp2 et methodes de traitement du cancer |
| US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
| EP3694848A1 (fr) | 2017-10-12 | 2020-08-19 | Revolution Medicines, Inc. | Pyridine, pyrazine et composés de triazine utilisés en tant qu'inhibiteurs allostériques de shp2 |
| EP3724189B1 (fr) | 2017-12-15 | 2023-10-04 | Revolution Medicines, Inc. | Composés polycycliques comme inhibiteurs allosteriques de la shp2 |
| US10561655B2 (en) | 2018-03-21 | 2020-02-18 | Synblia Therapeutics, Inc. | SHP2 inhibitors and uses thereof |
| EP3768668A1 (fr) | 2018-03-21 | 2021-01-27 | Relay Therapeutics, Inc. | Inhibiteurs de la phosphatase shp2 et leurs procédés d'utilisation |
| BR112020022224A2 (pt) | 2018-05-02 | 2021-06-08 | Navire Pharma, Inc. | inibidores heterocíclicos substituídos de ptpn11 |
| SG11202100199UA (en) | 2018-08-10 | 2021-02-25 | Navire Pharma Inc | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
| US11459340B2 (en) | 2018-09-18 | 2022-10-04 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors |
| CN112839935A (zh) * | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| EP4282416A3 (fr) * | 2018-09-29 | 2024-03-06 | Novartis AG | Procédé de fabrication d'un composé pour inhiber l'activité de shp2 |
| JP7386855B2 (ja) | 2018-09-29 | 2023-11-27 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物及び組成物の製造 |
| US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
| TW202028183A (zh) * | 2018-10-10 | 2020-08-01 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| PE20211465A1 (es) | 2018-10-17 | 2021-08-05 | Array Biopharma Inc | Inhibidores de la proteina tirosina fosfatasa |
| CN111138412B (zh) * | 2018-11-06 | 2023-09-15 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
| US20220127271A1 (en) | 2018-11-07 | 2022-04-28 | Shanghai Ringene Biopharma Co., Ltd. | Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use |
| TW202039498A (zh) | 2018-11-30 | 2020-11-01 | 大陸商上海拓界生物醫藥科技有限公司 | 嘧啶並五員氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
| WO2020156242A1 (fr) * | 2019-01-31 | 2020-08-06 | 贝达药业股份有限公司 | Inhibiteur de shp2 et son utilisation |
| WO2020156243A1 (fr) * | 2019-01-31 | 2020-08-06 | 贝达药业股份有限公司 | Inhibiteur de shp2 et son utilisation |
| SG11202109036WA (en) | 2019-03-01 | 2021-09-29 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
| MX2021010323A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| CN113795483A (zh) | 2019-03-07 | 2021-12-14 | 默克专利有限公司 | 作为shp2拮抗剂的甲酰胺-嘧啶衍生物 |
| CA3135555C (fr) * | 2019-04-02 | 2023-09-19 | Array Biopharma Inc. | Inhibiteurs de proteine tyrosine phosphatase |
| CN113646049A (zh) | 2019-04-08 | 2021-11-12 | 默克专利有限公司 | 作为shp2拮抗剂的嘧啶酮衍生物 |
| KR20220007889A (ko) | 2019-05-13 | 2022-01-19 | 릴레이 테라퓨틱스, 인크. | Fgfr 저해제 및 이의 사용 방법 |
| CN110003049A (zh) * | 2019-05-13 | 2019-07-12 | 苏州山青竹生物医药有限公司 | 一种制备4-氰基-1-茚酮的方法 |
| EP3972695A1 (fr) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1 |
| EP3984999A4 (fr) * | 2019-06-14 | 2023-11-22 | Beijing Shenogen Pharma Group Ltd. | Inhibiteur allostérique de la phosphatase shp2 |
| CA3142513A1 (fr) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Proteines de fusion flt3l-fc et procedes d'utilisation |
| AU2020306124A1 (en) | 2019-06-28 | 2022-02-03 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof |
| CN111704611B (zh) * | 2019-07-25 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类芳基螺环类shp2抑制剂化合物、制备方法和用途 |
| EP3772513A1 (fr) | 2019-08-09 | 2021-02-10 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Inhibiteurs d'shp2 |
| CA3154862A1 (fr) * | 2019-09-24 | 2021-04-01 | Relay Therapeutics, Inc. | Inhibiteurs de phosphatase shp2, procedes de production et d'utilisation associes |
| CN112574212B (zh) * | 2019-09-30 | 2022-04-19 | 上海拓界生物医药科技有限公司 | 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
| AU2020365113A1 (en) | 2019-10-18 | 2022-04-07 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
| CA3160142A1 (fr) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2021091982A1 (fr) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2021088945A1 (fr) | 2019-11-08 | 2021-05-14 | 南京圣和药业股份有限公司 | Composé utilisé comme inhibiteur de shp2 et son utilisation |
| MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| WO2021108683A1 (fr) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
| CA3165735A1 (fr) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Composes modulant la diacylglycerol kinase |
| CN113072499B (zh) * | 2020-01-03 | 2024-02-20 | 南京药石科技股份有限公司 | 一种4-氧代-8-氮杂螺[4．5]癸-2-烯-8-羧酸叔丁酯（苄酯）的制备方法 |
| WO2021147879A1 (fr) * | 2020-01-21 | 2021-07-29 | 贝达药业股份有限公司 | Inhibiteur de shp2 et son application |
| BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
| EP4110338A1 (fr) | 2020-02-28 | 2023-01-04 | Novartis AG | Combinaison pharmaceutique triple comprenant du dabrafénib, un inhibiteur d'erk et un inhibiteur de shp2 |
| TW202144334A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮雜芳類衍生物游離鹼的晶型 |
| CN113493440A (zh) * | 2020-04-03 | 2021-10-12 | 上海翰森生物医药科技有限公司 | 含氮杂芳类衍生物的盐及其晶型 |
| US20230039553A1 (en) | 2020-05-01 | 2023-02-09 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2021236775A1 (fr) * | 2020-05-19 | 2021-11-25 | The Regents Of The University Ofmichigan | Agents de dégradation à petites molécules de protéine shp2 |
| CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
| EP4208261A1 (fr) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Utilisation d'inhibiteurs de sos1 pour traiter des malignités à mutations de shp2 |
| PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
| CA3203111A1 (fr) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Inhibiteurs de sos1 et utilisations associees |
| WO2022156765A1 (fr) * | 2021-01-22 | 2022-07-28 | 南京明德新药研发有限公司 | Composé tricyclique lié à la pyrazolopyrazine et son application |
| EP4039685A1 (fr) | 2021-02-08 | 2022-08-10 | Irbm S.P.A. | Inhibiteurs azabicycliques de shp2 |
| JP2024509243A (ja) * | 2021-03-23 | 2024-02-29 | 上海海雁医薬科技有限公司 | 複素環置換ケトン類誘導体、その組成物および医薬における使用 |
| EP4067358A1 (fr) | 2021-04-02 | 2022-10-05 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Dérivés de (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[pipéridine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine et composés similaires en tant qu'inhibiteurs de shp2 pour le traitement par ex. du cancer |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| KR20240004960A (ko) | 2021-05-05 | 2024-01-11 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| CN115368373A (zh) | 2021-05-21 | 2022-11-22 | 石药集团中奇制药技术（石家庄）有限公司 | 螺环类化合物及其用途 |
| TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| CA3220923A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composes de modulation de la diacylglycerol kinase |
| WO2023280237A1 (fr) * | 2021-07-07 | 2023-01-12 | 海创药业股份有限公司 | Synthèse et utilisation d'agent de dégradation de phosphatase |
| AU2022309195A1 (en) * | 2021-07-09 | 2024-01-25 | Kanaph Therapeutics Inc. | Shp2 inhibitor and use thereof |
| CA3224341A1 (fr) | 2021-09-01 | 2023-03-09 | Novartis Ag | Combinaisons pharmaceutiques comprenant un inhibiteur de tead et leurs utilisations pour le traitement de cancers |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023076983A1 (fr) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Dérivés de pyridine-3(2h)-one |
| AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2023107956A1 (fr) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Protéines se liant à nkg2d, cd16 et 5t4 |
| WO2023107954A1 (fr) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Anticorps ciblant 5t4 et leurs utilisations |
| US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122581A2 (fr) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CN114524772B (zh) * | 2022-02-28 | 2023-07-11 | 中国药科大学 | 一种含杂环串联类化合物及其制备方法与应用 |
| WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Ｋｒａｓ ｇ１２ｄ調節化合物 |
| WO2023230205A1 (fr) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Inhibiteurs de mek et leurs utilisations |
| WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024035830A1 (fr) | 2022-08-11 | 2024-02-15 | Relay Therapeutics, Inc. | Formes solides d'un inhibiteur de cdk |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024061298A1 (fr) * | 2022-09-22 | 2024-03-28 | 上海海雁医药科技有限公司 | Forme solide d'un dérivé de méthanone à substitution hétérocyclo et son utilisation |
| EP4345101A1 (fr) | 2022-09-29 | 2024-04-03 | Irbm S.P.A. | Dérivés d'azole utilisés en tant qu'inhibiteurs de shp2 |
Family Cites Families (167)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3377826B2 (ja) | 1993-05-06 | 2003-02-17 | ヘキスト・アクチェンゲゼルシャフト | 液晶組成物に使用するための新規化合物 |
| JP2002500618A (ja) | 1995-10-31 | 2002-01-08 | イーライ・リリー・アンド・カンパニー | 抗血栓性ジアミン |
| EP1154997A4 (fr) | 1999-01-26 | 2002-11-04 | Dana Farber Cancer Inst Inc | Composes pharmaceutiquement actifs et procedes d'utilisation |
| US7375125B2 (en) | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| EP1415987B1 (fr) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Composes heteroaromatiques azotes pour le traitement des maladies de cancer |
| US20050019424A1 (en) | 2001-12-21 | 2005-01-27 | Adams Paul E. | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| US6855709B2 (en) | 2002-02-22 | 2005-02-15 | Pharmacia & Upjohn Company | Pyridyl sulfone derivatives |
| DE10246657A1 (de) | 2002-10-07 | 2004-04-15 | Merck Patent Gmbh | Chirales Phenolderivat, dieses enthaltendes Flüssigkristallmedium, Verfahren zur Herstellung eines Flüssigkristallmediums und elektrooptische Flüssigkristallanzeige |
| EP2256116A3 (fr) | 2002-11-18 | 2011-11-16 | ChemoCentryx, Inc. | Arylsulfonamides |
| SE0203712D0 (sv) | 2002-12-13 | 2002-12-13 | Astrazeneca Ab | Novel compounds |
| WO2004074266A1 (fr) | 2003-02-07 | 2004-09-02 | Janssen Pharmaceutica N.V. | 1,2,4-triazines inhibant le vih |
| CA2515544A1 (fr) | 2003-02-11 | 2004-08-26 | Kemia Inc. | Composes destines au traitement d'une infection virale |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| US20040242886A1 (en) | 2003-04-30 | 2004-12-02 | Sandeep Gupta | Monocyclic diazodioxide based Bcl-2 protein antagonists related applications |
| US7393873B2 (en) | 2003-07-02 | 2008-07-01 | Merck & Co., Inc. | Arylsulfonamide derivatives |
| BRPI0412382A (pt) | 2003-07-08 | 2006-09-19 | Astrazeneca Ab | composto , método para a verificação de novos compostos medicinais que se ligam a e modulam a atividade, por agonismo , agonismo parcial, ou antagonismo, do receptor de acetilcolina nicotìnico alfa7, método de tratamento ou profilaxia de uma doença ou condição humana, método para tratamento de jetlag, induzindo interrupção de fumar, vìcio em nicotina, abstinência, dor, e para colite ulcerativa, composição farmacêutica, e, método de tratamento ou prevenção de uma condição ou distúrbio que surge da disfunção de neurotransmissão do receptor de acetilcolina nicotìnico em um mamìfero, e, uso de um composto |
| AU2004278382B2 (en) | 2003-09-30 | 2008-09-18 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| TW200528459A (en) | 2004-01-06 | 2005-09-01 | Achillion Pharmaceuticals Inc | Azabenzofuran substituted thioureas; inhibitors of viral replication |
| EP1704145B1 (fr) | 2004-01-12 | 2012-06-13 | YM BioSciences Australia Pty Ltd | Inhibiteurs selectifs de kinases |
| JP4845873B2 (ja) | 2004-03-03 | 2011-12-28 | ケモセントリックス インコーポレーティッド | 二環式および架橋した窒素複素環 |
| US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| CA2560286A1 (fr) | 2004-03-23 | 2005-09-29 | Banyu Pharmaceutical Co., Ltd. | Derive de la quinazoline ou de la pyridopyrimidine substituee |
| JP4865702B2 (ja) | 2004-05-03 | 2012-02-01 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害剤 |
| BRPI0512535A (pt) | 2004-06-24 | 2008-03-25 | Incyte Corp | compostos de piperidinas n-substituìdas, suas composições e métodos de modulações |
| US20070043057A1 (en) | 2005-02-09 | 2007-02-22 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
| CA2577588C (fr) | 2004-10-29 | 2013-09-10 | Tibotec Pharmaceuticals Ltd. | Derives de pyrimidine bicycliques inhibant le vih |
| GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| CN101087767A (zh) | 2004-12-23 | 2007-12-12 | 马林克罗特公司 | 荧光吡嗪衍生物及其在评估肾功能中的使用方法 |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| CA2597134C (fr) | 2005-02-04 | 2015-05-26 | Senomyx, Inc. | Composes comprenant des groupements heteroaryle lies et leur utilisationa titre de nouveaux modificateurs de saveur, agents gustatifs et rehausseurs de gout umami pour compositions comestibleslimentaires |
| ATE481407T1 (de) | 2005-02-16 | 2010-10-15 | Neurosearch As | Neue diazabicyclische arylderivate und medizinische verwendung dafür |
| WO2007046867A2 (fr) | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Derives de piperidine et leurs utilisations comme agents therapeutiques |
| ES2574014T3 (es) | 2005-05-30 | 2016-06-14 | Msd K.K. | Derivado de piperidina novedoso |
| JP2007013804A (ja) | 2005-07-01 | 2007-01-18 | Mitsubishi Electric Corp | 属性指定通信方法および通信装置 |
| AU2006303437B2 (en) | 2005-10-19 | 2012-06-28 | Grunenthal Gmbh | Novel vanilloid receptor ligands and their use for producing medicaments |
| WO2007057742A2 (fr) | 2005-11-18 | 2007-05-24 | Pfizer Products Inc. | Nouveaux derives de piperazinone |
| WO2007057775A1 (fr) | 2005-11-21 | 2007-05-24 | Pfizer Limited | Dérivés de spiropipéridine |
| EP1970375A4 (fr) | 2005-11-29 | 2010-06-02 | Toray Industries | Derive d'arylmethylene uree et utilisation de celui-ci |
| CN101346368A (zh) | 2005-12-21 | 2009-01-14 | 詹森药业有限公司 | 作为α2C－肾上腺素受体拮抗剂的取代的吡嗪酮衍生物 |
| EP1983992A4 (fr) | 2006-01-19 | 2010-08-18 | Abbott Lab | 2-imino-benzimidazoles |
| CN101374835B (zh) | 2006-01-30 | 2012-04-25 | 转化技术制药公司 | 作为PTPase抑制剂的取代的咪唑衍生物、组合物和使用方法 |
| EP2001880A2 (fr) | 2006-03-07 | 2008-12-17 | Array Biopharma, Inc. | Derives heterobicycliques de pyrazole et methodes d'utilisation |
| CN101426788A (zh) | 2006-04-20 | 2009-05-06 | 詹森药业有限公司 | 用作药物的取代吡嗪酮衍生物 |
| CA2649707A1 (fr) | 2006-05-22 | 2007-11-29 | Janssen Pharmaceutica N.V. | Derives de pyrazinone substitues a utiliser comme medicament |
| AR063707A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden. |
| US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| DE602007006531D1 (de) | 2006-10-04 | 2010-06-24 | Hoffmann La Roche | Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren |
| DE102007018150A1 (de) | 2007-04-16 | 2008-10-23 | Grünenthal GmbH | VR1-Rezeptor-Liganden und µ-Opioid-Rezeptor-Liganden zur Behandlung von Schmerz |
| WO2008100412A1 (fr) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Dérivés de la pipéridine |
| WO2008104077A1 (fr) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Inhibiteurs à petite molécule de protéines arginine méthyltransférases (prmt) |
| EP2131861A2 (fr) | 2007-03-01 | 2009-12-16 | Mallinckrodt Inc. | Petites molécules photoactives intégrées et leurs utilisations |
| MX2009009304A (es) | 2007-03-01 | 2009-11-18 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso. |
| WO2008112674A1 (fr) | 2007-03-12 | 2008-09-18 | Irm Llc | Composés et compositions comme inhibiteurs de l'activité du récepteur cannabinoïde 1 |
| CN101918403A (zh) | 2007-09-06 | 2010-12-15 | 阵列生物制药公司 | 作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物 |
| WO2009036066A1 (fr) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Inhibiteurs du récepteur du facteur de croissance endothélial vasculaire (vegfr) contenant une fraction de liaison au zinc |
| BRPI0817211A2 (pt) | 2007-09-20 | 2017-05-16 | Irm Llc | composto composições como moduladores da atividade de gpr119 |
| BRPI0817835A2 (pt) | 2007-10-18 | 2015-03-31 | Boehringer Ingelheim Int | Antagonistas cgrp |
| CA2703471A1 (fr) | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Antagonistes des canaux calciques de type t a base d'amide de pyrazinyle |
| CA2716747A1 (fr) | 2008-02-29 | 2009-09-03 | Schering Corporation | Modulateurs de l'activite gamma-secretase pour le traitement de la maladie d'alzheimer |
| MX2010010975A (es) | 2008-04-07 | 2010-11-01 | Amgen Inc | Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular. |
| AR071619A1 (es) | 2008-05-07 | 2010-06-30 | Galapagos Nv | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen. |
| EP2328586A2 (fr) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Dérivés pyridazinone substitués comme ligands des récepteurs de l'histamine-3 (h3) |
| JP2011524917A (ja) | 2008-06-20 | 2011-09-08 | メタボレックス， インコーポレイテッド | アリールｇｐｒ１１９作動薬およびその使用 |
| PL2331547T3 (pl) | 2008-08-22 | 2015-01-30 | Novartis Ag | Związki pirolopirymidynowe jako inhibitory CDK |
| US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
| ES2397934T3 (es) | 2008-12-17 | 2013-03-12 | Amgen Inc. | Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10 |
| EP2379529B1 (fr) | 2008-12-19 | 2015-06-10 | Boehringer Ingelheim International Gmbh | Antagonistes du cgrp |
| EP2377851A4 (fr) | 2008-12-25 | 2012-06-20 | Taisho Pharmaceutical Co Ltd | Dérivé d'isoquinoléine |
| CA2750035C (fr) | 2009-01-22 | 2018-02-27 | Unigene Laboratories Inc. | Traitement de l'obesite |
| WO2010086613A1 (fr) | 2009-01-30 | 2010-08-05 | Betagenon Ab | Composés utiles en tant qu'inhibiteurs tel que ampk |
| WO2010103547A2 (fr) | 2009-03-13 | 2010-09-16 | Advinus Therapeutics Private Limited | Composés de pyrimidine fusionnée substituée |
| CN102596923B (zh) | 2009-07-08 | 2015-04-29 | 波罗的海生物公司 | 1,2,4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途 |
| MX353747B (es) | 2009-08-17 | 2018-01-26 | Memorial Sloan Kettering Cancer Center Star | Compuesto de union a proteina de choque termico, composiciones, y metodos para producir y usar los mismos. |
| US20120157471A1 (en) | 2009-09-01 | 2012-06-21 | Pfizer Inc. | Benzimidazole derivatives |
| KR20120092629A (ko) | 2009-10-09 | 2012-08-21 | 아이알엠 엘엘씨 | Ｇｐｒ119 활성의 조절제로서의 화합물 및 조성물 |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| MX2012006776A (es) | 2009-12-14 | 2012-10-05 | Merck Patent Gmbh | Inhibidores de la esfingosina quinasa. |
| CN102791687B (zh) | 2009-12-18 | 2015-02-11 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| US8431575B2 (en) | 2010-02-18 | 2013-04-30 | Transtech Pharma, Inc. | Phenyl-heteroaryl derivatives and methods of use thereof |
| MX2012011912A (es) | 2010-04-13 | 2012-11-16 | Novartis Ag | Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer. |
| CN102947295B (zh) | 2010-04-29 | 2016-01-20 | 爱丁堡大学 | 作为11β-HSD1抑制剂的3,3-二取代的-(8-氮杂双环[3.2.1]辛烷-8-基)-[5-(1H-吡唑-4基)-噻吩-3-基]-甲酮 |
| WO2011146401A1 (fr) | 2010-05-17 | 2011-11-24 | Intermune, Inc. | Nouveaux inhibiteurs de la réplication du virus de l'hépatite c |
| US8969349B2 (en) | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
| AU2011283684B2 (en) | 2010-07-29 | 2015-08-27 | Rigel Pharmaceuticals, Inc. | AMPK-activating heterocyclic compounds and methods for using the same |
| JP2013230986A (ja) | 2010-08-25 | 2013-11-14 | Kyorin Pharmaceutical Co Ltd | 新規ヒダントイン誘導体及びそれらを有効成分とする医薬 |
| CN102432598A (zh) | 2010-09-29 | 2012-05-02 | 江苏恒瑞医药股份有限公司 | 三环化合物、其制备方法及其在医药上的应用 |
| GB201020161D0 (en) | 2010-11-26 | 2011-01-12 | Almac Discovery Ltd | Pharmaceutical compounds |
| CA2818903C (fr) | 2010-12-14 | 2021-03-23 | Electrophoretics Limited | 5-(1,3-benzoxazol-2-yl)-4-(pyridine-4-yl)pyrimidine-2-amine et son utilisation comme inhibiteur de caseine kinase 1 delta |
| WO2012088438A1 (fr) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions et méthodes utilisables en vue du traitement de maladies |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| US10280171B2 (en) | 2016-05-31 | 2019-05-07 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| AU2012249240A1 (en) | 2011-04-29 | 2013-11-07 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitors |
| WO2012158784A2 (fr) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulateurs des récepteurs orphelins apparentés aux récepteurs hormonaux nucléaires |
| EP2554544A1 (fr) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK |
| WO2013039851A1 (fr) | 2011-09-12 | 2013-03-21 | Mallinckrodt Llc | Agents optiques permettant d'obtenir des images de métalloprotéases matricielles et de les visualiser |
| JP6061949B2 (ja) | 2011-12-12 | 2017-01-18 | レセプトス エルエルシー | 糖尿病などの疾患の治療のためのｇｌｐ−１受容体モジュレーターとして作用する４つの環を含むカルボン酸誘導体 |
| US10934487B2 (en) | 2012-02-22 | 2021-03-02 | Merck Patent Gmbh | Liquid crystalline medium |
| GB201204985D0 (en) | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| RU2632899C2 (ru) | 2012-04-25 | 2017-10-11 | Раквалиа Фарма Инк. | Амидопроизводные как блокаторы ttx-s |
| WO2013167633A1 (fr) | 2012-05-09 | 2013-11-14 | Basf Se | Composés d'acrylamide pour la lutte contre des animaux nuisibles invertébrés |
| WO2014000178A1 (fr) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Dérivés de sulfamide et leurs méthodes d'utilisation permettant d'améliorer la pharmacocinétique d'un médicament |
| RU2665462C2 (ru) | 2012-06-27 | 2018-08-30 | Ф. Хоффманн-Ля Рош Аг | Соединения 5-азаиндазола и способы их применения |
| JP6254163B2 (ja) | 2012-08-16 | 2017-12-27 | ザ スクリプス リサーチ インスティテュート | 新規カッパオピオイドリガンド |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| US9527857B2 (en) | 2013-03-15 | 2016-12-27 | GI Therapeutics, Inc. | HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| KR20150128863A (ko) | 2013-03-15 | 2015-11-18 | 에프. 호프만-라 로슈 아게 | RORc 조절제로서 아릴 설파미드 및 설파메이트 유도체 |
| WO2014184014A1 (fr) | 2013-05-15 | 2014-11-20 | Basf Se | Composés de n-(1,2,5-oxadiazol-3-yl)carboxamide et leur utilisation en tant qu'herbicides |
| WO2014184074A1 (fr) | 2013-05-15 | 2014-11-20 | Basf Se | Composés de n-(tétrazol-5-yl)- et n-(triazol-5-yl)hétarylcarboxamide substitués et leur utilisation en tant qu'herbicides |
| GB201309508D0 (en) | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| EA030857B1 (ru) | 2013-06-11 | 2018-10-31 | Селджин Интернэшнл Ii Сарл | Новые модуляторы рецептора glp-1 |
| CA2953482A1 (fr) | 2013-07-03 | 2015-01-08 | Indiana University Research & Technology Corporation | Inhibiteurs de shp2 et methodes de traitement de maladies auto-immunes et associees a la glomerulonephrite a l'aide d'inhibiteurs de shp2 |
| US20160159773A1 (en) | 2013-07-30 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3027625B1 (fr) | 2013-07-31 | 2018-05-30 | Merck Sharp & Dohme Corp. | Derives spiro-fusionnes de piperidine utiles dans le traitement, entre autres, de l'hypertension et de l' insuffisance cardiaque aiguë ou chronique |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| CA2926571C (fr) | 2013-10-08 | 2022-05-17 | Qing-bin LU | Composes anticancereux non a base de platine destines a etre utilises dans la chimiotherapie-cible |
| AU2014340318B2 (en) | 2013-10-21 | 2019-01-17 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| EP2883934B1 (fr) | 2013-12-16 | 2019-11-13 | Merck Patent GmbH | Support à cristaux liquides |
| JP2017503778A (ja) | 2013-12-19 | 2017-02-02 | バイエル ファーマ アクチエンゲゼルシャフト | アドレナリン受容体α２Ｃ拮抗薬としての置換されたビピペリジニル誘導体 |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
| JP6473457B2 (ja) | 2014-01-17 | 2019-02-20 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| MA39337B1 (fr) | 2014-02-14 | 2019-11-29 | Takeda Pharmaceuticals Co | Modulateurs de pyrazines de gpr6 |
| WO2015148714A1 (fr) | 2014-03-25 | 2015-10-01 | Duke University | Ligands de récepteurs de la protéine de choc thermique 70 (hsp-70) |
| AU2015243694B2 (en) | 2014-04-07 | 2019-01-17 | Netherlands Translational Research Center B.V. | (5,6-dihydro)pyrimido(4,5-e)indolizines |
| JP2017521480A (ja) | 2014-05-23 | 2017-08-03 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ベンゼンスルホンアミド誘導体及びｒｏｒｃモデュレーターとしてのその使用 |
| CN105294683B (zh) | 2014-07-26 | 2018-01-23 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| WO2016022645A1 (fr) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antagonistes hétérocycliques du récepteur du cgrp |
| WO2016022644A1 (fr) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antagonistes hétérocycliques des récepteurs cgrp |
| EP2985334B1 (fr) | 2014-08-15 | 2018-06-20 | Merck Patent GmbH | Milieu liquide cristallin |
| US9866893B2 (en) | 2014-08-19 | 2018-01-09 | Comcast Cable Communications, Llc | Methods and systems for accessing content |
| WO2016040449A1 (fr) | 2014-09-10 | 2016-03-17 | Raze Therapeutics, Inc. | Inhibiteurs de la 3-phosphoglycérate déshydrogénase) et leurs utilisations |
| TWI788655B (zh) | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| US9969719B2 (en) | 2015-03-11 | 2018-05-15 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug |
| WO2016151501A1 (fr) | 2015-03-25 | 2016-09-29 | Novartis Ag | Combinaisons pharmaceutiques |
| AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| WO2016197027A1 (fr) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll |
| CN112625028A (zh) * | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| WO2016203405A1 (fr) | 2015-06-19 | 2016-12-22 | Novartis Ag | Composés et compositions pour inhiber l'activité de shp2 |
| EP3310779B1 (fr) | 2015-06-19 | 2019-05-08 | Novartis AG | Composés et compositions pour l'inhibition de l'activité de shp2 |
| RU2604047C1 (ru) | 2015-07-10 | 2016-12-10 | Фортис Аксис, Закрытое Акционерное Общество | Массажёр для воздействия на мышцы спины трех отделов позвоночника |
| CA2998375A1 (fr) | 2015-09-17 | 2017-03-23 | Marvin J. Miller | Composes heterocycliques contenant de la benzylamine et compositions utiles contre une infection mycobacterienne |
| CN113549069A (zh) | 2015-12-27 | 2021-10-26 | 重庆复创医药研究有限公司 | 一类激酶抑制剂 |
| WO2017156397A1 (fr) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Inhibiteurs hétérocycliques de ptpn11 |
| US10570141B2 (en) | 2016-03-25 | 2020-02-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof |
| CN107286150B (zh) | 2016-04-11 | 2020-07-07 | 中国科学院上海有机化学研究所 | N-杂环类化合物、其中间体、制备方法、药物组合物和应用 |
| EP4108659A1 (fr) | 2016-06-07 | 2022-12-28 | Jacobio Pharmaceuticals Co., Ltd. | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs shp2 |
| EA036446B1 (ru) | 2016-06-14 | 2020-11-11 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
| CN116478132A (zh) * | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
| EP3290412A1 (fr) | 2016-08-31 | 2018-03-07 | Università degli Studi di Siena | Inhibiteurs des nucléocapsides du vih-1 |
| EP3515916B1 (fr) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation |
| WO2018089433A1 (fr) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | Inhibiteurs de mtorc phényle et leurs utilisations |
| JP2020503352A (ja) | 2017-01-03 | 2020-01-30 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
| AU2018239542C1 (en) * | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
| CN114213421A (zh) | 2017-04-01 | 2022-03-22 | 晟科药业（江苏）有限公司 | 1h-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂 |
| JP2020526557A (ja) | 2017-07-12 | 2020-08-31 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| EP3694848A1 (fr) | 2017-10-12 | 2020-08-19 | Revolution Medicines, Inc. | Pyridine, pyrazine et composés de triazine utilisés en tant qu'inhibiteurs allostériques de shp2 |
| EP3697759A4 (fr) | 2017-10-20 | 2021-05-12 | Vanderbilt University | Antagonistes du récepteur muscarinique de l'acétylcholine m4 |
| AU2018392805A1 (en) | 2017-12-22 | 2020-05-07 | Dana-Farber Cancer Institute, Inc. | NEK inhibitors and methods of use |
| KR20200116481A (ko) | 2018-01-29 | 2020-10-12 | 메르크 파텐트 게엠베하 | Gcn2 억제제 및 이의 용도 |
| SG11202006832YA (en) | 2018-01-29 | 2020-08-28 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
| WO2019152454A1 (fr) | 2018-01-30 | 2019-08-08 | Research Development Foundation | Inhibiteurs de shp2 et méthodes d'utilisation associées |
| AU2019216793B2 (en) | 2018-02-08 | 2023-02-02 | Enyo Pharma | Fused thiophene derivatives and their uses |
| US11466016B2 (en) | 2018-03-02 | 2022-10-11 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical compounds |
| JP7462951B2 (ja) | 2018-03-21 | 2024-04-08 | リャオ，シビン | Ｊａｋ阻害剤 |
-
2018
- 2018-03-23 AU AU2018239542A patent/AU2018239542C1/en active Active
- 2018-03-23 MA MA049013A patent/MA49013A/fr unknown
- 2018-03-23 EA EA201992253A patent/EA201992253A1/ru unknown
- 2018-03-23 US US16/496,655 patent/US10988466B2/en active Active
- 2018-03-23 KR KR1020247005342A patent/KR20240026521A/ko active Application Filing
- 2018-03-23 KR KR1020217033740A patent/KR20210130254A/ko not_active Application Discontinuation
- 2018-03-23 CA CA3057582A patent/CA3057582C/fr active Active
- 2018-03-23 MX MX2019011330A patent/MX2019011330A/es unknown
- 2018-03-23 NZ NZ758458A patent/NZ758458A/en unknown
- 2018-03-23 SG SG11201908820V patent/SG11201908820VA/en unknown
- 2018-03-23 WO PCT/IB2018/051973 patent/WO2018172984A1/fr unknown
- 2018-03-23 TW TW107110157A patent/TWI664175B/zh active
- 2018-03-23 EA EA202190196A patent/EA202190196A1/ru unknown
- 2018-03-23 KR KR1020197031080A patent/KR102317480B1/ko active IP Right Grant
- 2018-03-23 EP EP18770877.1A patent/EP3601239A4/fr active Pending
- 2018-03-23 JP JP2019551940A patent/JP6878615B2/ja active Active
- 2018-03-23 KR KR1020227026278A patent/KR20220113545A/ko not_active Application Discontinuation
-
2019
- 2019-09-23 MX MX2021013686A patent/MX2021013686A/es unknown
- 2019-09-23 CL CL2019002698A patent/CL2019002698A1/es unknown
- 2019-09-23 PH PH12019502175A patent/PH12019502175A1/en unknown
- 2019-09-23 MX MX2021013683A patent/MX2021013683A/es unknown
- 2019-09-23 MX MX2021013685A patent/MX2021013685A/es unknown
- 2019-10-22 CO CONC2019/0011678A patent/CO2019011678A2/es unknown
-
2020
- 2020-11-13 AU AU2020267305A patent/AU2020267305A1/en not_active Abandoned
- 2020-12-29 CL CL2020003425A patent/CL2020003425A1/es unknown
-
2021
- 2021-04-27 JP JP2021074668A patent/JP2021121592A/ja active Pending
-
2022
- 2022-06-30 AU AU2022204681A patent/AU2022204681B2/en active Active
- 2022-11-08 JP JP2022178608A patent/JP2023011889A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49013A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| MA45189A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA46339A (fr) | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| MA46196A (fr) | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal | |
| MA45660A (fr) | 3-méthylpyrazines 2,5-disubstituées et 3-méthyl pyrazines 2,5,6-trisubstitués en tant qu'inhibiteurs allostériques de shp2 | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA45153A (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA44498A (fr) | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA47086A (fr) | Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase | |
| MA53352A (fr) | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase | |
| MA44502A (fr) | Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA43862A (fr) | Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock | |
| MA42659A (fr) | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp | |
| MA48987A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue |